(12) **Translation of European patent specification**

(11) **NO/EP 2970120 B1**

(19) NO

NORWAY

(51) Int Cl.

C07D 213/04 (2006.01)
A61K 31/44 (2006.01)
A61K 31/505 (2006.01)
A61P 35/00 (2006.01)
C07D 239/24 (2006.01)
C07D 239/42 (2006.01)
C07D 401/12 (2006.01)
C07D 401/14 (2006.01)
C07D 403/12 (2006.01)
C07D 403/14 (2006.01)
C07D 405/06 (2006.01)
C07D 405/10 (2006.01)
C07D 405/12 (2006.01)
C07D 405/14 (2006.01)
C07D 413/12 (2006.01)
C07D 417/12 (2006.01)
C07D 471/04 (2006.01)
C07D 487/04 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2019.01.21
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.09.12
(86)	European Application Nr.	14764299.5
(86)	European Filing Date	2014.03.14
(87)	The European Application's Publication Date	2016.01.20
(30)	Priority	2013.03.15, WO, PCT/CN13/072690
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Hutchison Medipharma Limited, Building 4, 720 Cailun Road Hi-tech Park, Shanghai 201203, Kina
(72)	Inventor	SU, Wei-Guo, Building 4720 Cailun RoadZJ. Hi-Tech Park, Shanghai 201203, Kina ZHANG, Weihan, Building 4720 Cailun RoadZJ. Hi-Tech Park, Shanghai 201203, Kina LI, Jinshui, Building 4720 Cailun RoadZJ. Hi-Tech Park, Shanghai 201203, Kina
(74)	Agent or Attorney	TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54) Title **NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE**

(56) References Cited: WO-A1-2004/065378, WO-A1-2013/129369, WO-A1-2013/133351, WO-A1-2010/086646, WO-A2-2007/056075

Patentkrav

1. Forbindelse med formel (I):



(I)

eller et farmasøytisk akseptabelt salt derav,
hvori
X er CH_2, Y er valgt blant CH_2, O eller $S(O)_2$; eller X og Y sammen med bindingen derimellom danner -CH=CH- eller -C≡C-;
G er N eller CH;
R^1 er aryl eller heteroaryl, hver av disse er eventuelt substituert med én eller flere substituenter uavhengig valgt blant halogen, $-NR^6R^7$, $-OR^8$, $-S(O)_nR^9$, $-(CH_2)_r-C(O)R^{10}$, -CN, $-C(O)NR^6R^7$, $-NR^6C(O)R^{10}$, $-NR^6S(O)_nR^9$, $-NR^6S(O)_nNR^{11}R^{12}$, $-NR^6C(O)OR^8$, $-NR^6C(O)NR^{11}R^{12}$, $-NO_2$, $-S(O)_nNR^6R^7$, okso, eventuelt substituert alkyl, $-(CH_2)_p-$ eventuelt substituert sykloalkyl, $-(CH_2)_m-$ eventuelt substituert heterosyklyl, $-(CH_2)_q-$ eventuelt substituert heteroaryl, eventuelt substituert alkenyl, og eventuelt substituert alkynyl;
R^2 er uavhengig valgt blant eventuelt substituert C_1-C_6alkyl, eventuelt substituert C_1-C_6alkoksy, eller eventuelt substituert C_3-C_8sykloalkyl;
R^3, R^4 er uavhengig valgt blant hydrogen, halogen, -CN, eller eventuelt substituert C_1-C_6alkyl,
R^5 er C_1-C_6alkyl,
eller R^3 og R^5 sammen med O-atomet som R^5 er festet til, og bindingen derimellom danner en 5- eller 6-leddet oksygenholdig heterosyklisk ring;
n er 1 eller 2;
m, p, q og r er uavhengig valgt blant 0, 1, 2, 3, 4, 5, 6;
R^6, R^7, R^8, R^9, R^{10}, R^{11} og R^{12} er uavhengig valgt blant hydrogen, alkyl, sykloalkyl, aryl, heteroaryl, heterosyklyl, som hver med unntak av hydrogen, eventuelt er substituert med ett eller flere substituenter uavhengig valgt blant halogen, hydroksyl, merkapto, okso, alkyl, sykloalkyl, heterosyklyl, eventuelt substituert amino og eventuelt substituert amid,
hvori hver eventuelt substituerte gruppe ovenfor som substituenten(e) ikke er spesifikt angitt for, kan være usubstituert eller uavhengig substituert med én eller flere, så som en, to eller tre substituenter uavhengig valgt blant C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl,

sykloalkyl, aryl, heterosyklyl, heteroaryl, aryl-C_1-C_6alkyl-, heteroaryl-C_1-C_6alkyl-, C_1-C_6halogenalkyl-, -OC_1-C_6alkyl, -OC_2-C_6alkenyl, -OC_1-C_6alkylfenyl, -C_1-C_6alkyl-OH, -C_1-C_6alkyl-SH, -C_1-C_6alkyl-O-C_1-C_6alkyl, -OC_1-C_6halogenalkyl, halogen, -OH, merkapto, -NH_2, -C_1-C_6alkyl-NH_2, -N(C_1-C_6alkyl)$_2$, -NH(C_1-C_6alkyl), -N(C_1-C_6alkyl)(C_1-C_6alkylfenyl), -NH(C_1-C_6alkylfenyl), cyano, nitro, okso, -C(O)-OH, -C(O)OC_1-C_6alkyl, -CON(C_1-C_6alkyl)$_2$, -CONH(C_1-C_6alkyl), -$CONH_2$, -NHC(O)(C_1-C_6alkyl), -NHC(O)(fenyl), -N(C_1-C_6alkyl)C(O)(C_1-C_6alkyl), -N(C_1-C_6alkyl)C(O)(fenyl), -C(O)C_1-C_6alkyl, -C(O)C_1-C_6alkylfenyl, -C(O)C_1-C_6halogenalkyl, -OC(O)C_1-C_6alkyl, -S(O)$_2$-C_1-C_6alkyl, -S(O)-C_1-C_6alkyl, -S(O)$_2$-fenyl, -S(O)$_2$-C_1-C_6halogenalkyl, -S(O)$_2NH_2$, -S(O)$_2$NH(C_1-C_6alkyl), -S(O)$_2$NH(fenyl), -NHS(O)$_2$(C_1-C_6alkyl), -NHS(O)$_2$(fenyl), og -NHS(O)$_2$(C_1-C_6halogenalkyl).

2. Forbindelsen med formel (I) ifølge krav 1, hvori hver eventuelt substituerte gruppe som substituenten(e) ikke er spesifikt angitt for, kan være usubstituert eller uavhengig substituert med én eller flere substituenter uavhengig valgt blant hydroksyl, merkapto, halogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, -OC_1-C_6alkyl, -NH_2, -N(C_1-C_6alkyl)$_2$, -NH(C_1-C_6alkyl), cyano, nitro, okso, -S(O)$_2$-C_1-C_6alkyl, -S(O)-C_1-C_6alkyl, -S(O)$_2$-C_1-C_6halogenalkyl, -C(O)-OH, -C_1-C_6alkyl-OH, -C_1-C_6 alkyl-SH, heterosyklyl, eller et farmasøytisk akseptabelt salt derav.

3. Forbindelsen med formel (I) ifølge krav 1 eller 2, hvori R^1 er aryl eller heteroaryl, hvor hver av disse eventuelt er substituert med én eller flere substituenter uavhengig valgt blant:

(1) halogen;

(2) okso;

(3) eventuelt substituert alkyl;

(4) -(CH_2)$_m$- eventuelt substituert heterosyklyl;

(5) -(CH_2)$_p$- eventuelt substituert syklosyklyl;

(6) -(CH_2)$_q$- eventuelt substituert heteroaryl;

(7) -S(O)$_n$$R^9$;

(8) -(CH_2)$_r$-C(O)R^{10};

(9) eventuelt substituert alkenyl;

(10) eventuelt substituert alkynyl;

(11) -OR^8;

hvori n er 1 eller 2; m, p, q og r er uavhengig valgt blant 0, 1, 2, 3, 4, 5, 6; R^8, R^9 og R^{10} er uavhengig valgt blant hydrogen, alkyl, heterosyklyl, som hver med unntak av hydrogen, eventuelt er substituert med én eller flere substituenter uavhengig valgt blant alkyl, okso, heterosyklyl;

hvori "eventuelt substituert alkyl", "eventuelt substituert heterosyklyl", "eventuelt substituert sykloalkyl", "eventuelt substituert heteroaryl", "eventuelt substituert alkenyl" og "eventuelt substituert alkynyl" i R^1 ovenfor kan være usubstituert eller uavhengig substituert med én eller flere substituenter uavhengig valgt blant hydroksyl, merkapto, halogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, -OC_1-C_6 alkyl, -NH_2, -$N(C_1$-C_6alkyl$)_2$, -$NH(C_1$-C_6alkyl), cyano, nitro, okso, -$S(O)_2$-C_1-C_6alkyl, -$S(O)$-C_1-C_6alkyl, -$S(O)_2$-C_1-C_6 halogenalkyl, -C(O)-OH, -C_1-C_6alkyl-OH, -C_1-C_6 alkyl-SH, heterosyklyl, eller et farmasøytisk akseptabelt salt derav.

4. Forbindelsen med formel (I) ifølge krav 3, hvori R^1 er aryl eller heteroaryl, hvor hver av disse eventuelt er substituert med én eller flere substituenter uavhengig valgt blant:
(1) halogen;
(2) okso;
(3) alkyl eventuelt substituert med én eller flere substituenter uavhengig valgt blant hydroksyl, merkapto, halogen, -OC_1-C_6alkyl, -NH_2, -$N(C_1$-C_6alkyl$)_2$, -$NH(C_1$-C_6alkyl), cyano, nitro, -$S(O)_2$-C_1-C_6alkyl, -$S(O)$-C_1-C_6 alkyl, -C(O)-OH;
(4) -$(CH_2)_m$-heterosyklyl eventuelt substituert med én eller flere substituenter uavhengig valgt blant C_1-C_6alkyl, -C_1-C_6alkyl-OH, -C_1-C_6 alkyl-SH og okso, hvori m er 0, 1, 2, 3, 4, 5 eller 6;
(5) -$(CH_2)_p$-usubstituert sykloalkyl, hvori p er 0, 1, 2, 3, 4, 5 eller 6;
(6) -$(CH_2)_q$-heteroaryl eventuelt substituert med én eller flere substituenter uavhengig valgt blant C_1-C_6alkyl, hvori q er 0, 1, 2, 3, 4, 5 eller 6;
(7) -$S(O)_nR^9$, hvori R^9 er C_1-C_6alkyl, og n er 1 eller 2;
(8) -$(CH_2)_r$-$C(O)R^{10}$, hvori R^{10} er heterosyklyl eventuelt substituert med én eller flere substituenter uavhengig valgt blant C_1-C_6 alkyl og okso, hvori r er 0, 1, 2, 3, 4, 5 eller 6;
(9) usubstituert C_2-C_6alkenyl;
(10) usubstituert C_2-C_6alkynyl;
(11) -OR^8, hvori R^8 er valgt blant hydrogen, alkyl eventuelt substituert med én eller flere substituenter uavhengig valgt blant heterosyklyl,
eller et farmasøytisk akseptabelt salt derav.

5. Forbindelsen med formel (I) ifølge krav 1, hvori R^1 er aryl eller heteroaryl, hvor hver av disse eventuelt er substituert med én eller flere substituenter uavhengig valgt blant:
(1) halogen;
(2) -NR^6R^7, hvori R^6 og R^7 er uavhengig er valgt blant hydrogen og C_1-C_6 alkyl eventuelt substituert med amino som eventuelt er substituert med C_1-C_6alkyl;

(3) -OR^8, hvori R^8 er valgt blant hydrogen og C_1-C_6alkyl eventuelt substituert med én eller flere substituenter uavhengig valgt blant: heterosyklyl eventuelt substituert med -OH eller merkapto, og amino eventuelt substituert med C_1-C_6alkyl,

(4) -$S(O)_nR^9$, hvori R^9 er C_1-C_6alkyl, og n er 1 eller 2;

(5) -$(CH_2)_r$-$C(O)R^{10}$, hvori R^{10} C_1-C_6alkyl, eller heterosyklyl eventuelt substituert med én eller flere substituenter uavhengig valgt blant C_1-C_6alkyl og okso, hvori r er 0, 1, 2, 3, 4, 5 eller 6;

(6) -CN;

(7) -$C(O)NR^6R^7$, hvori R^6 og R^7 er uavhengig valgt blant hydrogen og C_1-C_6alkyl eventuelt substituert med amino som eventuelt er substituert med C_1-C_6alkyl;

(8) -$NR^6C(O)R^{10}$, hvori R^6 er H, og R^{10} er C_1-C_6alkyl;

(9) okso;

(10) alkyl eventuelt substituert med én eller flere substituenter uavhengig valgt blant hydroksyl, merkapto, halogen, -OC_1-C_6alkyl, -NH_2, -$N(C_1$-C_6alkyl$)_2$, -$NH(C_1$-C_6alkyl), cyano, nitro, -$S(O)_2$-C_1-C_6alkyl, -$S(O)$-C_1-C_6alkyl, -$C(O)$-OH;

(11) -$(CH_2)_p$-usubstituert sykloalkyl, hvori p er 0, 1, 2, 3, 4, 5 eller 6;

(12) -$(CH_2)_m$-heterosyklyl eventuelt substituert med én eller flere substituenter uavhengig valgt blant C_1-C_6alkyl, C_3-C_8sykloalkyl, -C_1-C_6alkyl-OH, -C_1-C_6alkyl-SH, -C_1-C_6alkyl-O-C_1-C_6alkyl, -NH_2, -$N(C_1$-C_6alkyl$)_2$, -$NH(C_1$-C_6alkyl), okso, -$C(O)C_1$-C_6alkyl, hvori m er 0, 1, 2, 3, 4, 5 eller 6;

(13) -$(CH_2)_q$-heteroaryl eventuelt substituert med én eller flere substituenter uavhengig valgt blant C_1-C_6alkyl, hvori q er 0, 1, 2, 3, 4, 5 eller 6;

(14) usubstituert C_2-C_6alkenyl;

(15) usubstituert C_2-C_6alkynyl;

eller et farmasøytisk akseptabelt salt derav.

6. Forbindelsen med formel (I) ifølge krav 4 eller 5, hvori R^1 er et radikal til ringen eller ringsystemet valgt blant





hvor hver av disse eventuelt er substituert som definert i krav 4 eller 5, eller et farmasøytisk akseptabelt salt derav.

7. Forbindelsen med formel (I) ifølge krav 4 eller 5, hvori R^1 er valgt blant



hvor hver av disse eventuelt er substituert som definert i krav 4 eller 5, eller et farmasøytisk akseptabelt salt derav.

8. Forbindelsen med formel (I) ifølge krav 1, hvori R^8 er hydrogen eller C_1-C_6alkyl som eventuelt er substituert med heterosyklyl, eller et farmasøytisk akseptabelt salt derav.

9. Forbindelsen med formel (I) ifølge krav 1, hvori R^{10} er heterosyklyl eventuelt substituert med én eller flere substituenter uavhengig valgt blant C_1-C_6alkyl og okso, eller et farmasøytisk akseptabelt salt derav.

10. Forbindelsen med formel (I) ifølge krav 1, hvori R^1 er aryl eventuelt substituert med én eller flere substituenter uavhengig valgt blant: (1) halogen; (2) alkyl eventuelt substituert med -C(O)-OH; (3) -$(CH_2)_m$-heterosykyl- eventuelt substituert med én eller

flere substituenter uavhengig valgt blant C_1-C_6alkyl, -C_1-C_6alkyl-OH, -C_1-C_6alkyl-SH og okso, hvori m er 0, 1, 2, 3, 4, 5 eller 6; (4) -$(CH_2)_q$-heteroaryl eventuelt substituert med én eller flere substituenter uavhengig valgt blant C_1-C_6alkyl, hvori q er 0; (5) -$(CH_2)_r$-C(O)R^{10}, hvori R^{10} er heterosyklyl eventuelt substituert med én eller flere substituenter uavhengig valgt blant C_1-C_6alkyl og okso, hvori r er 0; (6) usubstituert C_2-C_6alkenyl; (7) usubstituert C_2-C_6alkynyl; (8) -OR^8, hvori R^8 er valgt blant hydrogen, alkyl, eventuelt substituert med én eller flere substituenter uavhengig valgt blant heterosyklyl,
eller et farmasøytisk akseptabelt salt derav.

11. Forbindelsen med formel (I) ifølge et hvilket som helst av kravene 1 til 10, hvori R^1 er fenyl substituert med piperazinyl, hvor piperazinyl eventuelt er substituert med ett eller flere C_1-C_6alkyl eller C_3-C_8sykloalkyl, fortrinnsvis C_1-C_6alkyl, mer foretrukket er R^1 fenyl substituert med piperazinyl, som eventuelt er substituert med ett eller flere metyl eller etyl, eller et farmasøytisk akseptabelt salt derav.

12. Forbindelsen med formel (I) ifølge krav 11, hvori R^1 er fenyl substituert med piperazinyl, hvor piperazinyl eventuelt er substituert med ett eller flere C_1-C_6alkyl, fortrinnsvis er R^1 fenyl substituert med piperazinyl, som eventuelt er substituert med ett eller flere metyl eller etyl, eller et farmasøytisk akseptabelt salt derav.

13. Forbindelsen med formel (I) ifølge krav 1, hvori R^1 er pyrazolyl, som eventuelt er substituert med én eller flere substituenter valgt blant:
(1) alkyl eventuelt substituert med én eller flere substituenter uavhengig valgt blant hydroksyl, merkapto, halogen, -OC_1-C_6alkyl, -NH_2, -$N(C_1$-C_6alkyl$)_2$, -$NH(C_1$-C_6alkyl), -$S(O)_2$-C_1-C_6alkyl, -S(O)-C_1-C_6alkyl;
(2) -$(CH_2)_m$-heterosyklyl eventuelt substituert med én eller flere substituenter uavhengig valgt blant C_1-C_6alkyl, hvori m er 0, 1, 2, 3, 4, 5 eller 6;
(3) -$(CH_2)_p$-usubstituert sykloalkyl, hvori p er 0, 1, 2, 3, 4, 5 eller 6;
(4) -$(CH_2)_q$-heteroaryl eventuelt substituert med én eller flere substituenter uavhengig valgt blant C_1-C_6alkyl, hvori q er 0, 1, 2, 3, 4, 5 eller 6;
(5) -$S(O)_nR^9$, hvori R^9 er C_1-C_6alkyl, og n er 1 eller 2;
(6) -$(CH_2)_r$-C(O)R^{10}, hvori R^{10} er heterosyklyl eventuelt substituert med én eller flere substituenter uavhengig valgt blant C_1-C_6 alkyl og okso, hvori r er 0, 1, 2, 3, 4, 5 eller 6;
eller et farmasøytisk akseptabelt salt derav.

14. Forbindelsen med formel (I) ifølge et hvilket som helst av kravene 1 til 13, hvori R^2 er valgt blant C_1-C_6alkyl, C_1-C_6alkoksy eventuelt substituert med hydroksyl, eller C_3-

C_8sykloalkyl, eller et farmasøytisk akseptabelt salt derav.

15. Forbindelsen med formel (I) ifølge krav 14, hvori R^2 er metyl, etyl, metoksy, etoksy substituert med hydroksyl, isopropoksy eller syklopropyl, eller et farmasøytisk akseptabelt salt derav.

16. Forbindelsen med formel (I) ifølge et hvilket som helst av kravene 1 til 13, hvori R^3, R^4 er uavhengig av hverandre valgt blant hydrogen, halogen, -CN, eller usubstituert C_1-C_6alkyl, R^5 er C_1-C_6alkyl, eller R^3 og R^5 sammen med O-atomet som R^5 er festet til, og bindingen derimellom danner en 5- eller 6-leddet oksygenholdig heterosyklisk ring, eller et farmasøytisk akseptabelt salt derav.

17. Forbindelsen med formel (I) ifølge et hvilket som helst av kravene 1 til 13, hvori R^4 er hydrogen, og R^3 og R^5 sammen med O-atomet som R^5 er festet til, og bindingen derimellom danner furan- eller dihydrofuranring, eller et farmasøytisk akseptabelt salt derav.

18. Forbindelsen med formel (I) ifølge krav 1, hvori forbindelsen er valgt blant forbindelsene 1-228, 230-299, 301-309:

1		155	
2		156	
3		157	

4		158	
5		159	
6		160	
7		161	
8		162	
9		163	
10		164	

11		165	
12		166	
13		167	
14		168	
15		169	
16		170	
17		171	

18		172	
19		173	
20		174	
21		175	
22		176	
23		177	
24		178	

25		179	
26		180	
27		181	
28		182	
29		183	
30		184	
31		185	

32		186	
33		187	
34		188	
35		189	
36		190	
37		191	
38		192	

39		193	
40		194	
41		195	
42		196	
43		197	
44		198	
45		199	

46		200	
47		201	
48		202	
49		203	
50		204	
51		205	
52		206	

53		207	
54		208	
55		209	
56		210	
57		211	
58		212	
59		213	

60		214	
61		215	
62		216	
63		217	
64		218	
65		219	
66		220	

67		221	
68		222	
69		223	
70		224	
71		225	
72		226	
73		227	

74		228	
75		230	
76		231	
77		232	
78		233	
79		234	
80		235	

81		236	
82		237	
83		238	
84		239	
85		240	
86		241	
87		242	

88		243	
89		244	
90		245	
91		246	
92		247	
93		248	
94		249	

95		250	
96		251	
97		252	
98		253	
99		254	
100		255	
101		256	

102		257	
103		258	
104		259	
105		260	
106		261	
107		262	
108		263	

109		264	
110		265	
111		266	
112		267	
113		268	
114		269	
115		270	

116		271	
117		272	
118		273	
119		274	
120		275	
121		276	
122		277	

123		278	
124		279	
125		280	
126		281	
127		282	
128		283	
129		284	

130		285	
131		286	
132		287	
133		288	
134		289	
135		290	
136		291	

137		292	
138		293	
139		294	
140		295	
141		296	
142		297	
143		298	

144		299	
145		301	
146		302	
147		303	
148		304	
149		305	
150		306	

151		307	
152		308	
153		309	
154			

eller et farmasøytisk akseptabelt salt derav.

19. Forbindelsen med formel (I) ifølge et hvilket som helst av kravene 1-18, og/eller et farmasøytisk akseptabelt salt derav for anvendelse som et medikament.

20. Farmasøytisk sammensetning som omfatter minst én forbindelse med formel (I) ifølge et hvilket som helst av kravene 1-18 og/eller minst ett farmasøytisk akseptabelt salt derav og eventuelt minst én farmasøytisk akseptabel bærer.

21. Forbindelsen med formel (I) ifølge et hvilket som helst av kravene 1-18, og/eller et farmasøytisk akseptabelt salt derav for anvendelse ved behandling av en sykdom som reagerer på inhibering av FGFR, hvori sykdommen som reagerer på inhibering av FGFR, er kreft.

22. Forbindelsen med formel (I) for anvendelse ifølge krav 21, hvori kreften er lungekreft, magekreft, leverkreft, brystkreft, eggstokkreft, endometriekarsinom eller blærekarsinom.